Companies Directory

PHARMADAX focuses on developing and manufacturing specialty generic medicines. We commenced our business in 2008 and headquartered in Taipei, Taiwan. Our Vision is to build a leading generic specialty pharmaceutical company with enhanced focus on specialty modified release products and become preferred development partner for global organizations. We are present in US, EU, China and Taiwan and expanding presence in other emerging markets through dossier registrations. Our manufacturing site is located in China with facility accredited by USFDA.

Over than 15 years PharmaDeal assists Pharma, Biotech, Cosmetic and Food Companies in Latam Region. We are a Contract Service Organization (CSO) and Contract Research Organization (CRO). Our Business Units: Business Development & RA Services: Start- up New Companies in Brazil Prospect New Products to be Commercialized in Brazil/Latam In/Out Licensing Products Liaison to find local Partner, Distributor and/or Wholesale Regulatory Consultancies & Product Registration and Tech Transfer Regulatory Inspections for MoH GMP Approval RA Due Diligences Clinical Research Services: Protocol Design Regulatory Affairs Submissions Study Management & Monitoring Quality Assurance Training Services: Focused in Clinical Research Focused in Marketing & Sales Contact us: pharmadeal@pharmadeal.com.br

As the founder of the modular delivery concept for pharmaceutical facilities, Pharmadule started its business in Stockholm, Sweden in 1986. Since the start, more than 80 projects have been delivered using Pharmadule's modular facility concept. Leading global pharma companies are using the modular approach for their new manufacturing facilities worldwide. Since 2011, Pharmadule is part of Morimatsu Group, an international manufacturer of process equipment and modular process super skids. This strong combination has allowed Pharmadule Morimatsu to combine process equipment with modular facilities for delivery of turnkey solutions to our clients. Today, Morimatsu Group is a world leader in the delivery of innovative process solutions and modular facilities with more than 4,100 global employees. The Group has sales and engineering offices in Stockholm, Shanghai, Wuhan, Yokohama, New Jersey, Houston, Milano, Dublin and Mumbai. Pharmadule Morimatsu has a strong global presence with our engineering and manufacturing facilities in Shanghai, Japan and Malaysia. Today, Pharmadule Morimatsu designs and delivers modular projects to the Life Sciences and Consumer Products industries. The Pharmadule Way offers unique values.

Idealizada e fundada por profissionais que construíram juntos uma história de sucesso no mercado mundial da Medicina Estética com a marca de fios de ácido polilático (Silhouette Soft) – Silhouette Lift, presente em mais de 60 países, vendida em 2014 para a empresa britânica Sinclair IS Pharma SA. Pharmaesthetics, uma empresa com sede em Luxemburgo, surge para atender à necessidade de profissionais na procura por produtos que combinam tecnologia, segurança e eficácia – permitindo que os profissionais da saúde possam trabalhar respeitando e recuperando as características de cada paciente, seja estética ou terapêutica. Traz em seu portfolio soluções completas em preenchimento à base de Ácido Hialurônico reticulado para tratamentos estéticos e terapêuticos, uma linha de mesoterapia para a pele e cabelo, além da toxina botulínica tipo A para uso estético e terapêutico, e também uma linha de dermocosméticos com o objetivo de atender de forma particular o desejo e a necessidade de cada paciente. A empresa nasce com a missão de reinventar a nova geração de produtos para uso terapêutico e estético. Considerando a relevância do mercado brasileiro para os produtos terapêuticos, decidiu instalar uma unidade de produção de medicamento biológico e produtos para saúde e beleza na cidade de Pinhais, estado do Paraná.

PharmaFarm S.A. este o companie al cărei obiect de activitate îl reprezintă distribuţia en gross de produse farmaceutice și parafarmaceutice. Prioritatea PharmaFarm este furnizarea de servicii de cea mai înaltă calitate farmaciilor partenere, a unităților spitalicești, precum și a pacienților acestora.

Pharmaffair is a consulting firm that specializes in regulatory affairs for pharmaceuticals, biologics, medical devices, cosmetics, over-the-counter products, and natural health products.

PHARMAFIELD Groupe offre une gamme complète de prestations destinée à optimiser l’efficacité et la performance du "service"​ auprès des industries de santé. Grâce à l’ensemble des entités, PHARMAFIELD Groupe met à la disposition des laboratoires pharmaceutiques différents types de réseaux de promotion médicale et de vente en officine pour la métropole et les dom-tom. A partir de la définition d’un besoin, nous réalisons une étude approfondie et vous proposons la solution d’externalisation la plus pertinente incluant l'encadrement, une gestion administrative et un pilotage de mission intégrée. Notre expertise nous permet de proposer une analyse de votre environnement produit et d’y intégrer une stratégie de développement adaptée.

Mit PharmaFocus frei und unabhängig bleiben. Seit ihrer Gründung im Jahr 2001 setzt sich PharmaFocus als einziger pharmazeutischer Grosshandel exklusiv für die unabhängige Apotheke ein. PharmaFocus verzichtet immer wieder auf vielversprechende Geschäfte, weil die potentiellen Partner in direkter oder indirekter Konkurrenz zu Ihrer Apotheke stehen. Dieses Verhalten zeigt, dass wir ein loyaler und vertrauenswürdiger Partner sind, der von der Zukunft der unabhängigen Apotheke überzeugt ist. Unsere Unternehmensphilosophie setzt Ihre Unterstützung voraus, weshalb wir auf Sie zählen. Gemeinsam werden wir unabhängig bleiben!

PharmaFox develops innovative compounds until clinical phase 1/2 for the pharmaceutical market. As soon as the early development phase is completed PharmaFox expects interest from Pharma companies. In this case it is foreseen that the assets will be sold. Investing in PharmaFox is a relatively low risk investment and can generate a high upside potential. The innovative pharma approach applied by the founders is already substantially de-risked. The companies lead compound is active in a high profile muscle disease (sarcopenia) making an early sale with an attractive deal probable. The ultimate goal of the investments is to create an optimal and realistic exit opportunity.